The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000679381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/03/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
Scientific title
An Open-label, First-in-human, Exploratory Imaging Study of the DOTA-STR-17126 Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low-dose [177Lu]Lu-DOTA-STR-17126 in Patients with Advanced or Metastatic Cancer
Additional trial identifiers [1] 316747 0
nil
Universal Trial Number (UTN)
Trial acronym
DOTA-STR-17126
Related trial records

Health condition
Health condition(s) studied:
metastatic breast cancer 341980 0
metastatic prostate cancer 341981 0
Condition category
Condition code
Cancer 337172 337172 0 0
Breast
Cancer 338060 338060 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
In this study, participants receive one or two injections of radiopharmaceutical medicines that are designed to find cancer cells that carry a marker called GRPR (Gastrin-Releasing Peptide Receptor).
These medicines are called radiopharmaceuticals, which means they contain a very small amount of radioactivity that helps doctors take pictures of the cancer.

There are two parts to the intervention:
1. First Injection – Diagnostic Imaging Agent [68Ga]Ga-DOTA-STR-17126 (PET Scan Tracer).
This is the first medicine every participant receives. It is given once by the Nuclear Medicine Physician or Nuclear Medicine Technologist as a quick injection into a vein (IV bolus). After the injection, participants have PET/CT scans at several time points (around 15, 30, 60, 120 and 180 minutes).

Purpose:
To show whether the cancer has GRPR receptors.
To map where the cancer lesions are and how much of the tracer they absorb.
To determine whether the participant can go on to the second injection.
This tracer does not treat the cancer—its job is only to help visualise tumour sites.

2. Second Injection – Low-Dose Therapeutic/Imaging Agent
[177Lu]Lu-DOTA-STR-17126 (SPECT Scan Tracer)
Only participants whose PET scan shows “positive uptake” (meaning their tumours absorbed the first tracer) receive this second injection between Day 8 to Day 15,
It is given once, as a slow infusion over about 20–30 minutes by the Nuclear Medicine Physician or Nuclear Medicine Technologist.
After the infusion, participants have SPECT/CT scans at multiple times (about 30 minutes, 6 hours, 24 hours, Day 4, and Day 8).

Purpose:
To see how the medicine moves through the body.
To understand how much radiation different organs and tumours absorb (dosimetry).
To check safety and side effects.
To help determine what dose might be used for future therapeutic studies.
This is a very low dose of a therapy-type radiopharmaceutical, used only for imaging and safety assessment in this trial—not to treat the cancer.

What Participants Are Exposed To:
One radiopharmaceutical called ([68Ga]Ga-DOTA-STR-17126).
If their cancer shows GRPR-positive uptake, participants receive a second radiopharmaceutical called ([177Lu]Lu-DOTA-STR-17126).
The radiation exposure similar to standard nuclear medicine scans and considered low risk at the doses used. No chemotherapy, immunotherapy, or other experimental drugs are given as part of this study.



Intervention code [1] 333440 0
Early detection / Screening
Description of the comparator or control
There is no comparator in this study.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345474 0
Number of participants with adverse events (AEs), serious adverse events (SAEs), with abnormal laboratory parameters (hematology, blood chemistry, and urinalysis), abnormal Physical examinations findings
Timepoint [1] 345474 0
Day 1 to Day 43 post dose
Secondary outcome [1] 458876 0
Standardized Uptake Value (SUV) of [68Ga]Ga-DOTA-STR-17126
Timepoint [1] 458876 0
Day 2 post-dose for all participants
Secondary outcome [2] 458877 0
PET/CT image quality of [68Ga]Ga-DOTA-STR-17126
Timepoint [2] 458877 0
Time Frame: Day 2 post-dose for all participants
Secondary outcome [3] 458878 0
Concentration of [177Lu]Lu-DOTA-STR-17126 in blood
Timepoint [3] 458878 0
Time Frame: Day 1, Day 2, Day 4, Day 8 post-dose for all participants
Secondary outcome [4] 461787 0
Tumour to Background Ratio (TBR) of [68Ga]Ga-DOTA-STR-17126
Timepoint [4] 461787 0
Time Frame: Day 2 post-dose for all participants
Secondary outcome [5] 461788 0
Percentage of injected activity (%IA) in tumour and non-tumour organs, this will be assessed as a composite outcome.
Timepoint [5] 461788 0
Time Frame: Day 1, Day 2, Day 4, Day 8 post-dose for all participants
Secondary outcome [6] 461789 0
Calculation of absorbed dose (AD, mGy/MBq) of [68Ga]Ga-DOTA-STR-17126
Timepoint [6] 461789 0
Time Frame: Day 1 post-dose for all participants
Secondary outcome [7] 462112 0
Concentration of [68Ga]Ga-DOTA-STR-17126 in blood
Timepoint [7] 462112 0
Time Frame: Day 1, Day 2, Day 4, Day 8 post-dose for all participants
Secondary outcome [8] 462113 0
Calculation of absorbed dose (AD, mGy/MBq) of [177Lu]Lu-DOTA-STR-17126
Timepoint [8] 462113 0
Time Frame: Day 1 post-dose for all participants

Eligibility
Key inclusion criteria
1. Ability to understand and willingness to provide informed consent

2. Adults 18 years of age

3. Must have the following histologically or cytologically confirmed diagnosis of advanced or metastatic
i. breast cancer
ii. prostate cancer

4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

5. Participant must have clinical or radiological documented tumour progression as established by the Investigator within 30 days of signing consent for the study

6. Participants who have exhausted standard-of-care systemic therapies in their metastatic setting. At least one detectable by conventional imaging tumour lesion with any diameter of 1 cm in size

7. Participants must have adequate organ and bone marrow function, defined as follows:
i. Absolute neutrophil count (ANC) equal to 1000 cells/mm3
ii. Platelet count equal to 100,000/mm3
iii. Haemoglobin equal to 9.0 g/dL
iv. AST, ALT, alkaline phosphatase 3 times upper limit of normal (ULN) if there is no evidence of liver metastases or 5 times ULN in the presence of liver metastases
v. Total bilirubin equal to 2 times upper limit of normal (ULN)
vi. Creatinine equal to 2 times ULN and creatinine clearance (CrCL) equal to 60mL/min using the Cockcroft Gault equation (Appendix 2)
8. Able to remain still for up to 60 minutes per scan
9. Any other condition which, in the opinion of the Investigator, would preclude participation in this study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Known hypersensitivity to the investigational medicinal products (DOTA-STR-17126) or any of the excipients.

2. Participants with Class 3 or 4 New York Heart Association (NYHA) Congestive Heart Failure.

3. Average QTc (using the Fridericia correction calculation) > 470 msec for females and QTcF >450 msec for males on screening ECG or history of congenital long QT syndrome.

4. Clinically significant bleeding within two weeks prior to trial entry (i.e., gastrointestinal bleeding, intracranial bleeding).

5. Pregnant or lactating women.
i. For female participants of childbearing potential or male participants with female partner of childbearing potential, who are not willing to practice highly effective contraception during the trial and for at least 6 months after [177Lu] Lu-DOTA-STR-17126 administration
ii. Sexually active males must use a condom during intercourse while taking the drug and for 4 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. Female partners of childbearing potential should use highly effective contraceptive methods during and up to 6 months after stopping treatment.

6. Have any medical condition that impairs complete bladder emptying. Participants with permanent urinary indwelling catheter (IDC) or nephrostomy may be allowed to enrol on a case-by-case basis in discussion with Principal Investigator, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.

7. Major surgery, defined as any surgical procedure that involves general anaesthesia and a significant incision (i.e., larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 30 days before study day 1 or anticipated surgery within the subsequent 43 days (6 weeks).

8. Has an additional active malignancy requiring therapy within the past 2 years.

9. History of another malignancy within 3 years before study enrolment. A subject with the following malignancies is allowed if considered cured or unlikely to recur within 3 years:
i. Carcinoma of the skin without melanomatous features
ii. Curatively treated cervical carcinoma in situ
iii. Bladder tumours considered superficial such as non-invasive (T1a) and carcinoma in situ (T1s), thyroid papillary cancer with prior treatment

10. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy within 30 days prior to trial enrolment.

11. Psychiatric illness/social situations that would interfere with compliance with study requirements.

12. Cannot undergo PET/CT scanning because of weight limits (350 lbs or 160 kg).

13. Prior exposure to any other GRPR-targeting therapeutic agents.

14. Prior treatment with any systemic anti-cancer therapy including chemotherapy, immunotherapy, biological therapy, radiation therapy, biologic, hormonal or herbal therapy, or any investigational therapy or investigational device, unless:
i. Standard of care or maintenance therapy such as, luteinizing hormone-releasing hormone (LHRH) or gonadotropin releasing hormone (GnRH) for patients with prostate cancer; selective estrogen receptor modulators or aromatase inhibitors or GnRH inhibitors for breast cancer,
ii. Within more than 30 days of chemotherapy, herbal therapies and monoclonal antibodies,
iii. Within more than 5 half-lives for biologic/non-cytotoxic targeted agents,
iv. Within more than 8 weeks prior radiation therapies External Beam Radiotherapy (EBRT) and/or Radioligand Therapy (RLT). Focal palliative radiotherapy given within 8 weeks prior to the low dose of [177Lu] Lu-DOTA-STR-17126 may be approved on a case-by-case basis, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome,
v. For participants who received radiotherapy (EBRT and/or RLT) more than 8 weeks prior to the low dose of 177Lu-DOTA-STR-17126, efforts should be made to calculate the prior radiation absorbed dose to each critical organ such as the kidneys, liver, lungs, and bone marrow.

15. Patients with a history of inflammatory disease which according to the investigator may interfere with correct evaluation of radioactive uptake, especially those affecting the thoraco-abdominal cavities (i.e., autoimmune, granulomatous disease).

16. Any clinically significant toxicity (with the exception of alopecia) related to prior anti-tumour therapy not resolved to Grade 1 or baseline.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 0
Type of endpoint/s
Pharmacokinetics / pharmacodynamics
Statistical methods / analysis
This is a first-in-human exploratory Phase 0 imaging trial, and no formal hypothesis testing or inferential statistical modelling is planned. The analysis is descriptive, designed to characterise safety, imaging behaviour, biodistribution, dosimetry, and pharmacokinetics of the investigational radiopharmaceuticals.

Descriptive statistics only (counts, percentages, means, SDs, medians, ranges) are used for:
Safety outcomes
Imaging endpoints
PK
Dosimetry
Biodistribution


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29533 0
ICON Cancer Centre Theranostics - Hollywood - Nedlands
Recruitment postcode(s) [1] 45853 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 321349 0
Commercial sector/Industry
Name [1] 321349 0
Starget Pharma Inc.
Country [1] 321349 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Icon (Integrated Cancer Oncology Network)
Address
Country
Australia
Secondary sponsor category [1] 324090 0
None
Name [1] 324090 0
Address [1] 324090 0
Country [1] 324090 0
Other collaborator category [1] 283952 0
Commercial sector/Industry
Name [1] 283952 0
Green Light Clinical
Address [1] 283952 0
Country [1] 283952 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319884 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 319884 0
Ethics committee country [1] 319884 0
Australia
Date submitted for ethics approval [1] 319884 0
05/11/2025
Approval date [1] 319884 0
12/12/2025
Ethics approval number [1] 319884 0
2025-11-1840

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148718 0
Dr Nat Lenzo
Address 148718 0
Icon Cancer Centre Hollywood - Unit 10 - 12, Hollywood Medical Centre, 85 Monash Avenue, Nedlands WA 6009
Country 148718 0
Australia
Phone 148718 0
+61 491 978 187
Fax 148718 0
Email 148718 0
Contact person for public queries
Name 148719 0
Amma Owusu
Address 148719 0
Investigator Initiated Trials Team, Mr Duncan Colyer, Level 1/22 Cordelia St, South Brisbane QLD 4101
Country 148719 0
Australia
Phone 148719 0
+61 498 120 411
Fax 148719 0
Email 148719 0
Contact person for scientific queries
Name 148720 0
Nat Lenzo
Address 148720 0
Icon cancer centre Hollywood - Unit 10 - 12, Hollywood Medical Centre, 85 Monash Avenue, Nedlands WA 6009
Country 148720 0
Australia
Phone 148720 0
+61 491 978 187
Fax 148720 0
Email 148720 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Data will be aggregated.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.